Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand.

Recombinant envelope glycoproteins prepared from a subtype B (MN) strain and a subtype E (CM244) strain of HIV-1 were combined to create a bivalent vaccine (B/E) effective against viruses circulating in the United States and Asia. Combining the two antigens resulted in formulations that increased the breadth and potency of the inter-subtype neutralizing response. Antibodies to the bivalent vaccine formulation neutralized viruses possessing diverse phenotypes, including syncytia-inducing and non-syncytia-inducing primary isolates, viruses using either the CCR5 or the CXCR4 chemokine receptors, and viruses differing in their sensitivity to soluble CD4. These studies demonstrate for the first time that the magnitude and quality of the immune response to HIV-1 can be improved by combining recombinant envelope glycoproteins from different genetic subtypes.

Purification of insulin-like growth factor-I and related proteins using underivatized silica.

Adsorption chromatography using underivatized porous glass can be an effective capture step for the purification of recombinant proteins. Classical desorption techniques using chaotropic agents or harsh chemical solvents often result in elution of inactive material and may not be economical at the process scale. More recently, elution schemes have used tetramethylammonium chloride (TMAC) to obtain biologically active material. A TMAC elution was shown to be effective in the initial purification steps for the recovery of recombinant human insulin-like growth factor-I (rhIGF-I) from an Escherichia coli fermentation broth. However, TMAC also elutes other, more hydrophobic, proteins that are difficult to remove in subsequent purification steps. This paper describes the capture of IGF-I from a crude fermentation broth and a more specific elution using a combination of ethanol and NaCl rather than TMAC. This elution also can be used with other proteins including an IGF-I binding protein (BP3) expressed in mammalian cell culture.

sICAM-1 enhances cytokine production stimulated by alloantigen.

The leucocyte adhesion molecules lymphocyte functional antigen-1 (LFA-1; CD11a/CD18) and intercellular adhesion molecule-1 (ICAM-1; CD54) facilitate the cell-to-cell interactions which are required for the initiation of immune responses. The role of this interaction in the response to alloantigen was assessed by comparing the effects of monoclonal antibodies against these molecules to the effects of a soluble form of the ICAM-1 molecule in the mixed lymphocyte response (MLR). In contrast to the well-documented inhibitory effects of anti-ICAM-1 or anti-LFA-1 antibodies on mixed lymphocyte responses, we were unable to block these responses with the soluble form of ICAM-1 (sICAM-1). In contrast, the addition of sICAM-1 to these cultures resulted in a two- to sixfold enhancement in the T-cell proliferative response to alloantigen over the normal response. Unlike previous reports, the biological activity of sICAM-1 was not dependent on generation of a solid-phase form of the molecule. The enhanced proliferative response correlated with an increase in the level of TNF-alpha detected in the MLR supernatants and could be blocked by antibodies to TNF-alpha. sICAM-1 had no effect on proliferation or cytokine production in the absence of alloantigen. These results suggest that antibodies which block ICAM-1/LFA-1 not only block the adhesion which is required to stabilize cell-to-cell contact, but also block the costimulatory signal which is required for T-cell activation.